Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution ...
May 06 2020 - 8:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated
biologics contract development and manufacturing organization
(CDMO) working to improve patient lives by providing high quality
development and manufacturing services to biotechnology and
pharmaceutical companies, and Aragen Bioscience, a leading contract
research organization (CRO) focused on accelerating pre-clinical
biologics product development, today announced a co-marketing
agreement that will provide clients an integrated
“sequence-to-manufacturing” service. Under terms of the
non-exclusive agreement, the companies will offer customers
Aragen’s cell line development expertise integrated with Avid’s
upstream and downstream process development and analytical services
to drive efficiencies and reduce overall timelines for delivering
CGMP bulk drug substances.
“With pharmaceutical and biotechnology companies
focused on delivering their innovative medicines to patients as
quickly as possible, this alliance aims to speed the entire CGMP
manufacturing process by having a single, integrated team oversee a
single, integrated project timeline with significant built-in
process efficiencies,” said Timothy Compton, chief commercial
officer of Avid. “We view this collaboration with Aragen as a
significant win for current and future clients of both companies
and we are excited to contribute our deep CDMO expertise to the
partnership, particularly our more than 15 years of commercial
product manufacturing experience.”
“I am excited about this partnership that will
enable us to accelerate drug development timelines and deliver new
biologic therapeutics to patients faster by integrating two
best-in-class offerings to our customers,” said Axel Schleyer, CEO
of Aragen. “Our services in discovery, cell line development, which
includes our innovative RapTr™ platform, protein production and
preclinical testing are a great match with Avid’s clinical and
commercial manufacturing capabilities. We look forward to this
collaboration that advances novel ideas into breakthrough
medicines.”
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biopharmaceutical products
derived from mammalian cell culture. The company provides a
comprehensive range of process development, high quality CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With over 25 years
of experience producing monoclonal antibodies and recombinant
proteins in batch, fed-batch and perfusion modes, Avid's services
include CGMP clinical and commercial product manufacturing,
purification, bulk packaging, stability testing and regulatory
strategy, submission and support. The company also provides a
variety of process development activities, including cell line
development and optimization, cell culture and feed optimization,
analytical methods development and product
characterization. www.avidbio.com
About Aragen Bioscience,
Inc.
Aragen Bioscience, Inc., a wholly owned subsidiary of GVK BIO,
is a leading contract research organization based in the San
Francisco Bay Area. Aragen Bioscience offers a diverse set of in
vitro and in vivo services for the discovery, production,
characterization, activity and efficacy assessment and development
of biologic and diagnostic products. www.aragenbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Alexa Martinez
Aragen Bioscience, Inc.
408-201-3547
amartinez@aragenbio.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024